ABRYSVO
Oct 28, 2024
Pfizer’s ABRYSVO Outpaces GSK’s AREXVY with Expanded FDA Approval – But Can It Sustain the Momentum?
Pfizer’s ABRYSVO became the first and only RSV vaccine approved for use in adults under 50, offering the most extensive RSV vaccine coverage for adults. The label expansion announced on 22 October 2024 includes younger adults considered at higher risk for RSV-related lower respiratory tract disease (LRTD). &nb...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
